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Classical oestrogen receptor is not detectable in pancreatic
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Summary Recent reports have suggested the presence of oestrogen receptors (ER) in pancreatic carcinoma.
Therefore the tumour may be sensitive to hormone manipulation therapy.
We examined 23 biopsies of human pancreatic carcinoma tissue for the presence of ER. The tissue was
assayed by two methods: Iso-electric focusing (IEF) and ER-ICA an immunocytochemical assay. All biopsies
were tested with ER-ICA and ten by IEF. Each biopsy was assessed histologically for tumour content and 20
contained adenocarcinoma. None of the samples of pancreatic carcinoma were positive for ER using the
ER-ICA, and none demonstrated the binding peak typical of ER in the IEF assay.
These results suggest that in pancreatic carcinoma oestrogen receptor is either absent (or at very low levels),
or of a different type to that found in breast and uterine tissue. On theoretical grounds at least, this must raise
questions as to the oestrogen sensitivity of pancreatic cancer.
There is a body of evidence to suggest that oestrogens are
important in the normal functioning of the pancreas (Gross-
man et al., 1969; Sandberg & Rosenthal, 1979), and are
implicated as a factor in pancreatic disease (Davidoff et al.,
1973; Glueck et al., 1972; Greenberger et al., 1966). There is
also evidence for the presence of the oestrogen receptor (ER)
in normal pancreas and pancreatic cancer (Greenway et al.,
1981) and for prolonged survival in patients with unresec-
table pancreatic cancer treated with the oestrogen antagonist
agent tamoxifen (Theve et al., 1983; Tonnensen & Kamp-
Jensen, 1986).
In this study, human pancreatic carcinoma tissue was
assayed for the presence of oestrogen receptors (ER). Two
techniques were used, isoelectric focusing (IEF-a ligand bin-
ding assay) and an oestrogen receptor immunocytochemical
assay (ER-ICA).
Materials and methods
Most of the tissue for pancreatic ER analysis was obtained
during laparotomy as wedge (10 mm x 10-30 mm) or needle
biopsies (1 mm x 20 mm) and usually only one or two sam-
ples were taken. The remainder were percutaneous fine-
needle aspirations for cytology (FNAC). Although the
majority of biopsies were from the primary tumour itself,
some were from metastatic tumour in the presence of an
obvious pancreatic primary.
ER is noted for its temperature-dependent propensity to
degrade in biopsied tissue. Therefore, specimens were taken
directly from the surgeon in the operating theatre and frozen
in liquid nitrogen. The elapse of time from biopsy to freezing
was usually less than 60 s. The specimens were transported to
the laboratory in liquid nitrogen, in which they were stored
until assay.
Samples from two patients were taken as FNAC for ER-
ICA assay. The aspirate was spread over several clean,
marked glass microscope slides, fixed in acetone, then trans-
ferred into a storage medium (42.8 g sucrose, 0.33 g anhyd-
rous magnesium chloride, 250 ml glycerol, made up to 500 ml
with 0.01 M phosphate buffered saline) and maintained at
- 20°C until assay.
To validate the methods of biopsy, freezing, transport and
storage, breast tissue was also taken for IEF and ER-ICA
assays from eight women with breast cancer who underwent
mastectomy. All methods of biopsy were performed (Tru-cut
or Biopty needle, wedge biopsy and FNAC) and handling
and transport of the samples was identical to that used for
the pancreatic biopsies.
Isoelectric focusing
The technique of IEF is based on that described by Under-
wood et al. (1983). In outline, oestrogen receptor is identified
by incubation of cellular homogenate with a radio-labelled
ligand (3H-oestradiol) which is then isolated by isoelectric
focusing. Receptor-bound ligand appears as a specific peak
of radioactivity between the anode and cathode on the IEF
gel. A concentration of 10 fmol mg-' cellular protein or more
is considered to represent clinically significant ER levels and
designated 'ER positive'. The method has been shown to be a
sensitive, specific and reproducible ligand assay for ER
(Wrange et al., 1976; Gustafsson et al., 1978; Ferno et al.,
1983; Underwood et al., 1983) and of comparable sensitivity
to dextran coated charcoal (DCC) assay in our own
laboratory (Jackson et al., 1989).
Because of the tissue volume required by IEF (1 cm2 by
40ltm thick), the amount of tissue available was an impor-
tant determinant of which samples could be assayed and only
the wedge biopsies provided enough. All assays were carried
out in duplicate and adjacent sections were cut for haematox-
ylin and eosin (H&E) staining to assess tumour content. To
establish the protein content a simple dye-binding colorimet-
ric assay was used, based on the method of Bradford (1976),
(Bio-Rad protein assay, Bio-Rad Laboratories Ltd, Watford,
England).
After incubation with tritiated oestradiol (2, 4, 6, 7, 3H-
oestradiol in toluene and ethanol 9:1 v/v, activity measured
as 93 Ci mMol' 250 gl-1 ; Amersham International plc,
Aylesbury, England) isoelectric focusing was performed on
thin-layer polyacrylamide gel (245 x 110 x 1 mm, pH 3.5-
9.5, 2.4% w/v ampholine, LKB Ampholine PAG plates,
Pharmacia LKB Biotechnology, S-751 82 Uppsala, Sweden)
in a cold-room at 4°C. The pH gradient was confirmed with
'Electran' isoelectric point marker solution (pI range
4.7-10.6, BDH Chemicals Ltd).
After focusing was complete, each lane of the gel (contain-
ing a single sample) was cut into 18 slices between cathode
and anode and counted in a scintillation counter. The con-
centration of 3H-oestradiol (fmol mg-' protein) bound in
each slice was calculated and plotted against slice number.
The pH gradient across the IEF gel revealed that the pI of
ER (pH 6.5 to 6.7) corresponded to slice 9.
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ER-ICA
The ER-ICA (Abbott Laboratories Ltd, Diagnostics Div-
ision, Maidenhead, England) uses the monoclonal antibody
H222 SpT, a rat IgG antibody to estrophilin. It is reported to
have a strong positive correlation with standard radioligand
binding assays (Hawkins et al., 1986; Johnson et al., 1987;
McCarty et al., 1986; Charpin et al., 1986; Ozzello et al.,
1986; DeSombre et al., 1986; Jonat et al., 1986) and is of
comparable sensitivity for ER positive tissue (qv) to both
IEF and DCC assay in our own laboratory (Jackson et al.,
1989).
The assay uses a standard peroxidase-antiperoxidase tech-
nique on thin tissue sections mounted on glass microscope
slides. The sections were counterstained with 2% aqueous
methyl green which was preferred to haematoxylin because
faintly ER positive results in previous breast cancer studies
had been masked by the blue stain. The slides were subse-
quently examined under the light microscope using 250 x
magnification and ER staining assessed as absent, +, + +,
or + + +. H&E sections were also prepared to assess the
tumour content of the specimen.
Results
IEF
There was sufficient tissue available for IEF assay in ten of
the pancreas samples and six of the breast samples. Only
seven pancreatic biopsies were from the primary tumour and
of these, two contained 'moderate' amounts of tumour
(about 30-50%), three had minimal tumour (less than 30%,
though probably enough to detect ER if present) and two
contained normal pancreas. All three samples of metastatic
tumour contained moderate amounts of tumour. All but one
of the breast cancer biopsies contained moderate amounts of
tumour and all were taken from the primary.
The concentration of 3H-oestradiolmg' protein in pan-
cratic cancer tissue is plotted against slice number in Figure
la and for breast cancer samples in Figure lb. For clarity the
mean value calculated from all samples, and a bar represen-
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Figure 1 a and b, Pancreatic cancer (ten cases) and breast cancer
(six cases), results of IEF: concentration of bound 3H-oestradiol
at each slice of IEF gel, summarised as a mean value and range
(vertical bar).
ting the range, are plotted for each slice number. There was
no binding peak at slice 9 and therefore no ER was detected
in the pancreatic tissues assayed.
Expressed as means and range, certain trends are obscured
that may have some relevance: seven pancreas samples bound
3H-oestradiol at a concentration greater than 10 fmolmg-'
protein in the terminal slices. In all except one the increased
binding appeared in slices 17 and 18. In the exception it
appeared as a peak at slice 15. Four slices also had raised
binding levels in slices 6 and 7.
All but one of the breast cancer samples had a peak of
binding at slice 9 indicating the presence of ER.
ER-ICA
The ER-ICA assay was performed on all eight breast cancer
samples (tissue sections and cytology) and on pancreatic
cancer biopsies from 23 patients, 18 of which were from the
primary site. All but three cases had histological confirmation
of pancreatic carcinoma from at least one other biopsy. Of
these three, one was from a patient with chronic pan-
creatitits, based on the histological findings and the subse-
quent natural history of the disease, another was classified as
a cholangiocarcinoma and a third was considered to be
pancreatic carcinoma from the natural history and operative
findings despite negative histology.
There was considerable variation in tumour content and its
distribution within the samples and only 13 of the assayed
pancreatic carcinoma biopsies contained 'moderate' amounts
of tumour. Of these, four were samples of metastatic tumour.
Both cytology samples contained tumour cells. Four other
biopsies contained no tumour, though one was from a
patient with chronic pancreatitis. Four others contained
'minimal' tumour.
None of the pancreatic samples were positive for ER using
the ER-ICA assasy and all were assayed at least twice, with
the same result. In contrast all the breast cancers were
positive for ER, though four were only weakly so. The ER
control slides supplied with the kit (MCF-7 cells) confirmed
that the ER-ICA assay produced a positive result in ER
positive tissue.
Discussion
The presence of pancreatic oestrogen receptors was suggested
almost three decades ago when Ullberg and Bengtsson (1963)
noted the unexpected binding of 3H-oestradiol to normal
mouse pancreas. In later reports evidence accumulated for
the existence of an oestrogen binding protein in the pancreas
ofthe rat, baboon, dog and man, but the protein appeared to
differ from ER (Sandberg et al., 1973; Sandberg & Rosen-
thal, 1974; Rosenthal & Sandberg, 1978; Pousette et al.,
1982; Boctor et al., 1981; Boctor et al., 1983). In contrast,
other reports suggested that pancreatic cancer tissue did con-
tain ER. Stedman et al. (1980) detected 8S and 4S 3H-
oestradiol binding proteins in two samples of pancreatic
cancer. Greenway and co-workers found large quantities of a
high affinity oestrogen-binding substance (equilibrium con-
stant 109-100I1mol-1) in each of six specimens of human
pancreatic cancer and in pooled human foetal pancreas, but
not in normal human pancreas (Greenway et al., 1981). They
were unable to detect the lower affinity binding protein found
by Sandberg and Rosenthal (1979) in normal pancreas, and
they suggested that the latter workers had detected con-
tamination by sex-hormone-binding globulin rather than a
true pancreatic oestrogen binding protein. Satake et al.
(1982) also found high affinity 3H-oestradiol binding (Kd=
10-1 M) in both 7, 12-dimethylbenzanthracene-induced pan-
creatic cancer in rats and in one of seven human pancreatic
adenocarcinomata. In a study of oestrogen binding and its
influence on growth in four human pancreatic cancer cell
lines (Benz et al., 1986), high affinity binding was detected
(Kd = 1-9 nM) though this was of a different order of mag-
nitude to that found in two oestrogen receptor-containingER IS NOT DETECTABLE IN PANCREATIC CARCINOMA 505
breast cancer cell lines (MCF-7 and T47D, Kd< 1 nM). Oest-
rogens, androgens and antioestrogens had varying effects on
the different pancreatic cell lines. Only one of them,
MiaPaCa, was clearly stimulated by oestradiol.
In this study with human pancreatic adenocarcinoma, IEF
revealed no peak of radioactivity corresponding to the pI of
3H-oestradiol-ER complex recorded in breast tissue (Gustafs-
son et al., 1978). The frequent peaks at the anodal end of the
gel (slices 16-18) suggest a consistent binding of 3H-
oestradiol. Wrange et al. (1976) attributed this to protein
precipitates occurring below pH 4, with non-specific binding.
This group did note, that in the tissue they assayed (human
breast carcinoma), there was some displacement of bound
3H-oestradiol in this region by excess unlabelled oestradiol,
suggesting the presence of high affinity binding sites with a
different pl and, by implication, a different structure and
function from ER.
In the light of the IEF results those from the ER-ICA
assay, which is immunologically specific for ER, are not
surprising. Given the positive reaction with the kit control
slides and the breast cancers the results are unlikely to be due
to failure of the assay. The negative result may be due to
either a very low density of ER posiitve cells in samples with
relatively few tumour cells, or levels of ER below the
threshold detectable by the assays used and therefore prob-
ably of no clinical significance (DeSombre et al., 1986;
McClelland et al., 1986).
Only two samples assayed by IEF were taken from the
pancreatic primary and contained 'moderate' amounts of
tumour. It may be argued that there were too few samples
for IEF to adequately assess ER content in primary pan-
creatic carcinoma. As 18 pancreas samples assayed by ER-
ICA were from the primary tumour the criticism is less valid.
The therapeutic implication of these results is that hor-
monal manipulation therapy is unlikely to significantly
influence the course of the disease in patients with pancreatic
cancer. This contrasts with two reports from (uncontrolled)
clinical studies in which tamoxifen was used with an apparent
increase in the duration of survival of patients with pan-
creatic cancer (Theve et al., 1983; Tonnensen & Kamp-
Jensen, 1986). However, a placebo-controlled clinical trial
with tamoxifen performed during this study (Taylor et al., in
preparation) showed no therapeutic benefit. A similar clinical
trial from Norway (Bakkevold et al., 1990) and a trial com-
paring tamoxifen, cyproterone acetate and placebo from the
UK (Keating et al., 1989) also indicated no benefit.
The existing body of evidence suggests the presence in the
pancreas of an oestrogen binding protein, different from the
classical oestrogen receptor and possibly related to the con-
trol of acinar secretion. The evidence from this study
indicates either a complete absence of the classical ER, or at
least the absence ofclinically significant levels of ER, in both
pancreatic adenocarcinoma and pancreatic tissue in which
carcinoma had developed.
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